Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study

Bryan, Philip; Seabroke, Suzie; Wong, Jenny; Donegan, Katherine; Webb, Elizabeth; Goldsmith, Charlotte; Vipond, Caroline; Feavers, Ian M.

doi:10.1016/s2352-4642(18)30103-2

Cited by 56 publications

(59 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current published data suggest that the 4CMenB vaccine has limited, if any, effect on the carriage of MenB [112]. Although the 4CMenB vaccine is reactogenic [113], recent surveillance data do not support initial concerns with respect to increased risk of Kawasaki disease and seizures [114]. The 4CMenB vaccine has the potential to offer protection against meningococci belonging to other serogroups.…”

Section: Importance Of Menb Protein Vaccinesmentioning

confidence: 99%

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Acevedo

Bai

Borrow

et al. 2018

Expert Review of Vaccines

145

159

View full text Add to dashboard Cite

2019) The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and highrisk populations, Expert Review of Vaccines, 18:1, 15-30, ABSTRACT Introduction: The 2018 Global Meningococcal Initiative (GMI) meeting focused on evolving invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies worldwide, with emphasis on emerging antibiotic resistance and protection of high-risk populations. The GMI is comprised of a multidisciplinary group of scientists and clinicians representing institutions from several continents. Areas covered: Given that the incidence and prevalence of IMD continually varies both geographically and temporally, and surveillance systems differ worldwide, the true burden of IMD remains unknown. Genomic alterations may increase the epidemic potential of meningococcal strains. Vaccination and (to a lesser extent) antimicrobial prophylaxis are the mainstays of IMD prevention. Experiences from across the globe advocate the use of conjugate vaccines, with promising evidence growing for protein vaccines. Multivalent vaccines can broaden protection against IMD. Application of protection strategies to high-risk groups, including individuals with asplenia, complement deficiencies and human immunodeficiency virus, laboratory workers, persons receiving eculizumab, and men who have sex with men, as well as attendees at mass gatherings, may prevent outbreaks. There was, however, evidence that reduced susceptibility to antibiotics was increasing worldwide. Expert commentary: The current GMI global recommendations were reinforced, with several other global initiatives underway to support IMD protection and prevention. ARTICLE HISTORY

show abstract

Section: Importance Of Menb Protein Vaccinesmentioning

confidence: 99%

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Acevedo

Bai

Borrow

et al. 2018

Expert Review of Vaccines

145

159

View full text Add to dashboard Cite

show abstract

“…Additionally to the five aforementioned phase III clinical studies, safety data on the concomitant administration of 4CMenB and HRV were retrieved from a prospective surveillance study conducted among children up to 18 months of age who received 4CMenB as part of the NIP in the United Kingdom (UK). 30 The study revealed no significant safety concerns within 20 months following 4CMenB introduction. Evaluation of immunization records for HRV vaccine collected before and after 4CMenB introduction suggested that 4CMenB reactogenicity did not affect compliance with the recommended vaccination schedule, including the administration of HRV.…”

Section: Safetymentioning

confidence: 76%

“…The remaining four abstracts were considered not relevant with respect to objectives or did not report data on co-administration of RV and meningococcal vaccines. Eleven studies provided information on the safety profile of co-administration of RV vaccines and meningococcal vaccines [20][21][22][23][24][25][26][27][28][29][30] and five studies reported data on immunogenicity. 21,22,24,29,31 No studies presented data on vaccine efficacy.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic literature review on the safety and immunogenicity of rotavirus vaccines when co-administered with meningococcal vaccines

Pereira

Benninghoff

Moerman

2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This study is aimed to review the published evidence on safety, immunogenicity, and efficacy of rotavirus vaccines when co-administered with meningococcal vaccines in infants. A systematic literature search was performed in four databases containing peer-reviewed articles and conference abstracts. In total, twelve articles were included in the review; 11 provided information on safety and five on the immunogenicity of rotavirus vaccines following co-administration. No paper was found on efficacy. Additional routine vaccines were administered in all studies. The safety analysis was mainly focused on fever, vomiting, diarrhea, intussusception, and changes in eating habits. Overall, safety profiles and immune responses associated with rotavirus vaccination were comparable between infants co-administered with rotavirus and meningococcal vaccines and infants receiving rotavirus vaccines without meningococcal vaccines. Although data are limited, co-administration of rotavirus and meningococcal vaccines does not appear to interfere with the safety or immunogenicity of rotavirus vaccines.

show abstract

“…62 When considering all MenB disease, effectiveness of two doses of vaccine has been estimated at 82.9%. 62 No safety concerns have been observed following the vaccination of 1.29 million children aged 2-18 months with 3 million doses of 4CMenB; 63 however, further studies are required to determine the need for boosters and their frequency.…”

Section: N Meningitidis Serogroup(s)mentioning

confidence: 99%

Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Bai

Borrow

Bukovski

et al. 2019

Journal of Infection

View full text Add to dashboard Cite

The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at < 1 case per 10 0,0 0 0 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk * Corresponding author.

show abstract

Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study

Cited by 56 publications

References 21 publications

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Systematic literature review on the safety and immunogenicity of rotavirus vaccines when co-administered with meningococcal vaccines

Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Contact Info

Product

Resources

About